Ask VialBase
Research

A Study of Tirzepatide in Participants With Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — VialBase Research

Trial Summary

SURMOUNT-OSA evaluated tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity. OSA severity is closely tied to body weight, particularly visceral and upper airway fat deposition. This trial tested whether tirzepatide-induced weight loss could meaningfully reduce sleep apnea severity.

Design

  • Type: Randomized, double-blind, placebo-controlled, two studies (with and without CPAP)
  • Population: 469 adults with moderate-to-severe OSA (AHI 15+) and BMI 30+
  • Arms: Tirzepatide (10 or 15 mg) vs. placebo
  • Duration: 52 weeks
  • Primary endpoint: Change in AHI from baseline to week 52

Key Outcomes

  • Primary endpoint met with significant AHI reduction (reported mid-2024)
  • Mean AHI reduction: ~50-60% with tirzepatide vs. minimal change with placebo
  • ~40-50% of tirzepatide patients achieved AHI <5 (effective “cure” of sleep apnea)
  • Mean weight loss: ~18-20% with tirzepatide
  • Improvements in oxygen desaturation index, sleep quality measures, daytime sleepiness
  • Results published in NEJM (2024)

Significance for Peptide Research

This trial demonstrates that pharmacological weight loss with incretin peptides can effectively treat a structural/mechanical condition (upper airway obstruction). The near-normalization of AHI in many patients challenges the notion that OSA always requires device-based therapy. Strong evidence for the weight loss as disease modification paradigm in sleep medicine.

See Also